Cord blood antibody following maternal SARS-CoV-2 inactive vaccine (CoronaVac) administration during the pregnancy

Basit Öğe Kaydı
dc.authorid0000-0002-6833-5646en_US
dc.authorscopusid6507971898en_US
dc.authorwosidC-7080-2019en_US
dc.contributor.authorSoysal, Ahmet
dc.contributor.authorBilazer, Canan
dc.contributor.authorGönüllü, Erdem
dc.contributor.authorBarın, Emine
dc.contributor.authorÇivilibal, Mahmut
dc.date.accessioned2021-12-16T13:45:01Z
dc.date.available2021-12-16T13:45:01Z
dc.date.issued2021en_US
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalıen_US
dc.description.abstractMaternal vaccination with SARS-CoV-2 vaccines has not been well studied yet in terms of safety and efficacy for protecting the newborn by the placental passage of antibodies. We reported 34 years of old health care worker (HCW) without any known SARS-CoV-2 infection. She had the first dose of SARS-CoV-2 inactivated virus vaccine (CoronaVac, Sinovac Life Science Co, Ltd, Beijing, China) at a gestational age of 28 weeks. The second dose of vaccine was given four weeks later at a gestational age of 32 weeks. HCW did not report any vaccine-related adverse events after either the first or second dose of the vaccine. Three weeks after the second dose of the vaccine, her anti-receptor-binding domain (RBD) of SARS-CoV-2 spike protein antibody was 779 arbitrary units (AU) per ml. She gave a birth of 38 weeks three days gestation age of healthy, full-term girl with a birth weight of 2770 gr. The mother's anti-RBD antibody was 734 AU/ml, the infant's cord blood anti-RBD antibody level was 764 AU/ml, respectively, cord sera/maternal sera transfer ratio was 1,04. This infant is the first identified case of SARS-CoV-2 IgG antibodies detectable in cord blood after maternal vaccination with CoronaVac.en_US
dc.identifier.citationSoysal, A., Bilazer, C., Gönüllü, E., Barın, E. & Çivilibal, M. (2021). Cord blood antibody following maternal SARS-CoV-2 inactive vaccine (CoronaVac) administration during the pregnancy. Human Vaccines & Immunotherapeutics, 17(10), pp. 3484-3486. https://doi.org/10.1080/21645515.2021.1947099en_US
dc.identifier.doi10.1080/21645515.2021.1947099en_US
dc.identifier.endpage3486en_US
dc.identifier.issue10en_US
dc.identifier.pmidPMID: 34325615en_US
dc.identifier.scopus2-s2.0-85111862874en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage3484en_US
dc.identifier.urihttps://doi.org/10.1080/21645515.2021.1947099
dc.identifier.urihttps://hdl.handle.net/20.500.13055/86
dc.identifier.volume17en_US
dc.identifier.wosWOS:000679583200001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynak.otherSCI-E - Science Citation Index Expandeden_US
dc.institutionauthorGönüllü, Erdem
dc.language.isoenen_US
dc.publisherTaylor and Francisen_US
dc.relation.ispartofHuman Vaccines and Immunotherapeuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectSARS-CoV-2 Vaccineen_US
dc.subjectPregnancyen_US
dc.subjectCord Blooden_US
dc.subjectAntibodyen_US
dc.subjectCoronaVacen_US
dc.titleCord blood antibody following maternal SARS-CoV-2 inactive vaccine (CoronaVac) administration during the pregnancyen_US
dc.typeArticleen_US
dspace.entity.typePublication

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Cord blood antibody following maternal SARS CoV 2 inactive vaccine CoronaVac administration during the pregnancy.pdf
Boyut:
170.46 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Kapalı Erişim
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu